Mauna Kea Technologies reported H1 2026 sales of €3,203K, up 44% at constant exchange rates, driven by clinical adoption in the United States and rapid international expansion of CellTolerance. The company confirmed its trajectory toward profitability by year-end 2027, supported by a strengthened balance sheet and a solid systems pipeline for the second half of the year.

H1 2026 Sales Performance

Total sales for the first half reached €3,203K, compared to €2,303K in H1 2025. Growth was primarily led by the EMEA & ROW region, which surged 261% to €1,149K, while United States sales grew 10% at constant exchange rates to €2,055K. CellTolerance sales increased 142% year-over-year to €896K.

Regional and Operational Highlights

In the United States, sales growth was driven by robust probe sales, which increased 33% at constant exchange rates, and services, which rose 17%. The company noted strengthening pricing power, with average probe discounting falling from 23% in 2024 to 13% in 2026. While Q2 2026 U.S. sales declined 8% due to the phasing of system sales, the company expects a significant increase in the second half driven by pancreatic-cyst momentum and upgrade cycles.

EMEA and ROW sales grew significantly, up 261% in H1, driven by strong momentum in the CellTolerance application for food intolerances. The company successfully expanded into new territories, including the UAE, Switzerland, Australia, and Spain, and obtained regulatory approvals in the Middle East, Switzerland, and the UK.

Financial Position and Outlook

The company strengthened its financial flexibility in July 2026 with a €4 million optional shareholder loan facility from Vester Finance. This facility, drawable over 24 months, extends financial visibility beyond 2027. Combined with a €27 million debt reduction achieved through the 2025 restructuring, the company operates with an optimized cost structure.

Mauna Kea expects growth to continue in the second half of 2026, supported by increased U.S. system sales, acceleration in U.S. usage volumes, and the continued ramp-up of CellTolerance. The company confirmed its trajectory toward profitability by year-end 2027 and operational self-financing thereafter.

Mauna Kea Technologies will host a webinar on July 21, 2026, to review its business performance for the first half of 2026. The event aims to provide shareholders and the financial community with insights into the company's operational highlights during this period.

Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer, will deliver live commentary on the key developments. The session will include a question-and-answer segment to address investor queries.

Webinar Details

The webinar is scheduled for Tuesday, July 21, 2026. Participation requires advance registration. A replay of the session will be made available for those who register.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company specializing in the manufacture and sale of Cellvizio. This platform is a multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) system designed for real-time in vivo cellular imaging. The technology assists physicians in monitoring disease progression, assessing real-time reactions, classifying indeterminate areas, and guiding surgical interventions across various medical specialties.